Low expression of Foxo3a is Associated with Poor Prognosis in Ovarian Cancer Patients

REFERENCES

• van Houwelingen J.C., ten Bokkel Huinink W.W., van der Burg M. E.L., et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7: 769–773
   PubMed Web of Science ®Google Scholar
• Omura G. A., Brady M. F., Homesley H. D., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138–1150
   PubMed Web of Science ®Google Scholar
• Thigpen T., Brady M. F., Omura G. A., et al. Age as a prognostic factor in ovarian carcinoma. Cancer 1993; 71: 606–614
   PubMed Web of Science ®Google Scholar
• Holschneider C. H., Berek J. S. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3–10
   PubMed Web of Science ®Google Scholar
• Brunet A., Bonni A., Zigmond M. J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–868
   PubMed Web of Science ®Google Scholar
• Nakae J., Park B. C., Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999; 274: 15982–15985
   PubMed Web of Science ®Google Scholar
• Tang E. D., Nunez G., Barr F. G., Guan K. L. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274: 16741–16746
   PubMed Web of Science ®Google Scholar
• Rena G., Guo S., Cichy S. C., Unterman T. G., Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 1999; 274: 17179–17183
   PubMed Web of Science ®Google Scholar
• Takaishi H., Konishi H., Matsuzaki H., et al. Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci USA 1999; 96: 11836–11841
   PubMed Web of Science ®Google Scholar
• Del Peso L., Gonzalez V. M., Hernandez R., Barr F. G., Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 1999; 18: 7328–7333
   PubMed Web of Science ®Google Scholar
• Accili D., Arden K. C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421–426
   PubMed Web of Science ®Google Scholar
• Burgering B. M., Kops G. J. Cell cycle and death control: long live forkheads. Trends Biochem Sci 2002; 27: 352–360
   PubMed Web of Science ®Google Scholar
• Tran H., Brunet A., Griffith E. C., Greenberg M. E. The many forks in FOXO's road. Sci STKE 2003; RE5
   Google Scholar
• Milde-Langosch K., Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 2003; 196: 224–44
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396: 177–180
   PubMed Web of Science ®Google Scholar
• Lee M. H., Reynisdottir I., Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639–649
   PubMed Web of Science ®Google Scholar
• Polyak K., Lee M. H., Erdjument-Bromage H., et al. Cloning of p27Kip1, a cyclindependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59–66
   PubMed Web of Science ®Google Scholar
• Catzavelos C., Bhattacharya N., Ung Y. C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227–230
   PubMed Web of Science ®Google Scholar
• Porter P. L., Malone K. E., Heagerty P. J., et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222–225
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., Koff A., Drobnjak M., et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998; 90: 1284–1291
   PubMed Web of Science ®Google Scholar
• Mori M., Mimori K., Shiraishi T., et al. p27 expression and gastric carcinoma. Nat Med 1997; 3: 593
   PubMed Web of Science ®Google Scholar
• Esposito V., Baldi A., De Luca A., et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in nonsmall cell lung cancer. Cancer Res 1997; 57: 3381–3385
   PubMed Web of Science ®Google Scholar
• Florenes V. A., Maelandsmo G. M., Kerbel R., et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998; 153: 305–312
   PubMed Web of Science ®Google Scholar
• Loda M., Cukor B., Tam S. W., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231–234
   PubMed Web of Science ®Google Scholar
• Sui L., Dong Y., Ohno M., et al. Implication of malignancy and prognosis of p27kip1, cyclin E, and cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001; 83: 56–63
   PubMed Web of Science ®Google Scholar
• Erlanson M., Landberg G. Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 2001; 40: 461–70
   PubMed Web of Science ®Google Scholar
• Chandramohan V., Jeay S., Pianetti S., Sonenshein G. E. Reciprocal Control of Forkhead box O 3a and c-Myc via the Phosphatidylinositol 3-Kinase Pathway Coordinately Regulates p27Kip1 Levels. The Journal of Immunology 2004; 172: 5522–5527
   PubMed Web of Science ®Google Scholar
• Burgering B. M., Medema R. H. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003; 73: 689–701
   PubMed Web of Science ®Google Scholar
• Barbareschi M., Girlando S., Mauri F. M., et al. Quantitative growth fraction evaluation with MIBI and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994; 102: 171–175
   PubMed Web of Science ®Google Scholar
• de Riese W.T., Crabtree W. N., Allhoff E. P., et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 1993; 11: 1804–1808
   PubMed Web of Science ®Google Scholar
• Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13–20
   PubMed Web of Science ®Google Scholar
• Youssef E. M., Matsuda T., Takada N., et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the oesophagus. Cancer 1995; 76: 358–366
   PubMed Web of Science ®Google Scholar
• Carlsson P., Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002; 250: 1–23
   PubMed Web of Science ®Google Scholar
• Kaestner K. H., Knochel W., Martinez D. E. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14: 142–146
   PubMed Web of Science ®Google Scholar
• Kops G. J., Burgering B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 1999; 77: 656–665
   PubMed Web of Science ®Google Scholar
• Dijkers P. F., Medema R. H., Pals C., et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000; 20: 9138–9148
   PubMed Web of Science ®Google Scholar
• Hu M. C., Lee D. F., xiao W., et al. IkappaB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. Cell 2004; 117: 225–237
   PubMed Web of Science ®Google Scholar